

News Release

NOTAL VISION™
Your Sight is Our Vision

Notal Vision's ForeseeHome™ AMD Monitor Receives FDA Clearance

St. Louis, MO (December 28, 2009) – Notal Vision's ForeseeHome™ AMD Monitor has received Section 510 (k) clearance from the U.S. Food and Drug Administration (FDA).

The ForeseeHome AMD Monitor is the first ophthalmic device linking patients and doctors between eye exams for ongoing monitoring of Age-Related Macular Degeneration (AMD). Patients complete a frequent but brief exam on their ForeseeHome AMD Monitor in the comfort of their own home, and data is transmitted to the patient's eye care physician and the Notal Vision Data Monitoring Center via telephone line. The award winning ergonomic design of the ForeseeHome AMD Monitor is comfortable and easy to use for patients at risk of vision loss from wet AMD.

Wet AMD is the leading cause of blindness in people over age 50 in the western world. Recent breakthroughs in treatments place even greater importance on early detection of the devastating effects of wet AMD. Frequent monitoring is critical in detecting disease onset as early as possible and the ForeseeHome AMD Monitor is the first home monitoring device for following patients at risk of vision loss, offering hope for early intervention through early detection.

Numerous clinical studies have demonstrated the ForeseeHome AMD Monitor is an accurate and reliable tool for frequent monitoring of patients at risk of vision loss from AMD.

Notal Vision maintains a corporate office in Tel Aviv, Israel, where the company was founded and has recently established an office and distribution center in St. Louis, MO. Notal Vision plans to begin a limited commercial launch of the ForeseeHome AMD Monitor in the U.S. in 2010.

For more information, please visit www.notalvision.com.

About Notal Vision™

Notal Vision was founded in 2000 by ophthalmologists and medical professionals determined to reduce vision loss associated with Age-Related Macular Degeneration (AMD). With leading experts in the field, this team of medical professionals and scientists developed a new technology for monitoring AMD, the leading cause of significant vision loss and blindness in the western world. This new technology, Preferential Hyperacuity Perimetry, is now providing eye care professionals around the world with valuable clinical data for monitoring patients with AMD.

The Notal Vision management team consists of medical and business professionals with offices in Israel and the U.S.

For more information contact:

Jodi Wiener
Notal Vision
(877) 322-2207
jodi@notalvision.com